Sirnaomics Ltd.

Sirnaomics Ltd. (HKEX: 2257) is one of VASRO GmbH’s selected spotlight companies. We are pleased to share the company’s equity story and its clearly defined growth roadmap.

This publication offers a straightforward overview of Sirnaomics as a clinical-stage biotechnology company developing RNAi medicines, which silence a disease-causing gene before it is turned into protein. We focus on its two proprietary delivery platforms, PNP and GalAhead, the four programmes now in human trials and the fifth that is IND-ready, and the global rights the company holds across them. We examine the clinical record behind its lead candidate in skin cancer, the balance sheet and the cost reductions made since listing, the partnering and licensing routes open to the science, and the key risks and watchpoints that may shape earnings quality, capital allocation, and the broader equity story.

Download the Equity Report

Access the full Initial Equity Report